Prenatal Diagnosis of Downs Syndrome and other Trisomies
Indications and Risk Assessment
- Advanced maternal age is a primary risk factor for autosomal trisomies due to meiotic nondisjunction, particularly in the maternal gamete.
- The risk for Down syndrome (Trisomy 21) in newborns increases significantly with maternal age: 1:1550 at 15-29 years, 1:800 at 30-34 years, 1:270 at 35-39 years, 1:100 at 40-44 years, and 1:50 after 45 years.
- Invasive prenatal fetal karyotyping is routinely offered if the screening risk of bearing a child with Down syndrome exceeds 1:250.
- Genetic counseling and prenatal diagnosis are recommended for women 35 years of age or older at delivery, couples with a previous child with a chromosomal abnormality, or if prenatal screening tests return abnormal results.
Non-Invasive Screening Tests
- Prenatal screening aims to identify high-risk pregnancies using maternal serum markers, ultrasonography, and cell-free fetal DNA.
- First-trimester screening (dual test) combined with ultrasound markers achieves a high detection rate of 85-90% for aneuploidies.
- Non-invasive prenatal screening (NIPS) evaluates cell-free fetal DNA of trophoblastic or placental origin in the maternal blood after 10 weeks of gestation.
- NIPS utilizes next-generation sequencing (NGS) to screen for common aneuploidies involving chromosomes 13, 18, 21, X, and Y.
- NIPS possesses a highly accurate negative predictive value of 98-99%, though positive tests still require confirmation via invasive diagnostic procedures.
| Screening Modality | Trimester | Specific Markers / Analytes |
|---|---|---|
| First Trimester Serum | First | Pregnancy-associated plasma protein A (PAPP-A), Free human chorionic gonadotropin (hCG) |
| Second Trimester Serum (Triple/Quad Test) | Second | Alpha-fetoprotein (AFP), hCG, Unconjugated estriol, Inhibin A |
| Non-Invasive Prenatal Screening (NIPS) | First (after 10 weeks) | Cell-free fetal DNA in maternal plasma |
Maternal Serum Screening Profiles
- In pregnancies affected by Down syndrome, second-trimester screening reveals low levels of alpha-fetoprotein (AFP) and unconjugated estriol, accompanied by high levels of hCG.
- The detection rate for Down syndrome using the triple and quadruple tests in the second trimester is approximately 65% and 75%, respectively, with a 5% false-positive rate.
- In fetuses with Trisomy 18 (Edwards syndrome), all three primary markers (AFP, estriol, and hCG) are notably reduced.
Ultrasonography Findings in Trisomies
- Fetal ultrasonography is a robust, non-invasive tool to detect structural anomalies and markers that suggest a high risk for chromosomal abnormalities.
| Chromosomal Disorder | Trimester | Characteristic Ultrasound Findings |
|---|---|---|
| Trisomy 21 (Down Syndrome) | First | Increased nuchal translucency, absence of nasal bone |
| Trisomy 21 (Down Syndrome) | Second | Increased nuchal fold thickness, short femur and humerus, duodenal atresia, congenital heart defects (e.g., endocardial cushion defects) |
| Trisomy 18 (Edwards Syndrome) | Second/Third | Intrauterine growth restriction (IUGR), clenched hands with overlapping digits, prominent occiput, rocker-bottom feet, micrognathia, congenital heart and renal malformations, polyhydramnios |
| Trisomy 13 (Patau Syndrome) | Second/Third | Holoprosencephaly, cleft lip (often midline) and palate, microphthalmia, postaxial polydactyly, hypoplastic ribs, aplasia cutis congenita (scalp defects), cardiac anomalies |
| Monosomy X (Turner Syndrome) | First/Second | Increased nuchal fold thickness, severe lymphedema, fetal hydrops, coarctation of the aorta |
Invasive Diagnostic Procedures
- Invasive testing provides fetal cells for definitive chromosomal and molecular diagnosis, indicated when screening tests are positive or when maternal risk factors are highly significant.
- Positive NIPS or abnormal maternal serum screens must be confirmed using these invasive diagnostic modalities.
- Amniotic fluid is the preferred sample for traditional chromosomal studies, whereas chorionic tissue is frequently used for DNA-based tests and enzyme assays.
| Procedure | Gestational Timing | Tissue Sampled | Procedure-Related Risk |
|---|---|---|---|
| Chorionic Villus Sampling (CVS) | 10-12 or 11-12 weeks | Placental chorionic villi (transcervical or transabdominal) | 0.2-0.3% |
| Amniocentesis | 16-20 weeks | Amniotic fluid (containing desquamated fetal cells) | 0.2-0.3% |
| Cordocentesis | After 18 weeks | Fetal blood from the umbilical cord | Slightly higher than amniocentesis |
Laboratory Techniques for Fetal Tissue Analysis
- Conventional Karyotyping: Analyzes dividing cells in metaphase to detect numerical abnormalities (aneuploidies) and large structural rearrangements; results from amniotic fluid cultures typically take about two weeks.
- Fluorescence In Situ Hybridization (FISH): Utilizes fluorescent DNA probes targeting specific chromosomes (e.g., 13, 18, 21, X, and Y); provides rapid preliminary detection of common aneuploidies on uncultured interphase cells within 24 to 48 hours.
- Quantitative PCR (qPCR): A rapid and highly reliable molecular method used to amplify and quantify specific DNA sequences, delivering results for common aneuploidies in 24 to 48 hours.
- Chromosomal Microarray (CMA): An advanced molecular cytogenetic technique that screens the entire genome for copy number variations (microdeletions and microduplications) at a resolution 50-fold higher than karyotyping; it is highly recommended if ultrasound detects multiple congenital anomalies lacking a specific syndromic presentation.
Genetic Counseling and Recurrence Risk
- Genetic counseling must be provided with tact and truthfulness, informing parents about recurrence risks, prenatal testing options, and the scope of developmental potential and comorbidities of the fetus.
- Trisomy 21 is caused by a free trisomy in 95% of cases, while 4% are due to translocations (most commonly involving chromosomes 14 and 21), and 1% are mosaic.
- Parental karyotyping is explicitly required if a child or fetus is diagnosed with the translocation form of Down syndrome to determine if either parent is a balanced translocation carrier.
- For mothers aged 35 years or younger who have had a child with free trisomy 21, the recurrence risk in a subsequent pregnancy is approximately 1%.
- If a parent carries a balanced translocation, the recurrence risk rises significantly: approximately 10% if the mother is the carrier, and 4-5% if the father is the carrier.
- In the rare event of a 21;21 balanced robertsonian translocation [t(21q;21q)], the recurrence risk for Down syndrome in all viable fetuses is 100%.
- Recurrence risks for free Trisomy 18 and Trisomy 13 are approximately 1%, but this risk is elevated if the aneuploidy is a result of a parental balanced translocation.